Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update
Enliven Therapeutics reported a Q1 net loss of $23.6 million, narrowing from a $28.5 million loss in the prior year, while maintaining a cash position of $452.4 million. Management expects the current cash balance to fund operations into the first half of 2029, removing near-term financing risk as the company advances its pipeline.
Key figures
- Net loss
- 23627000
- Cash runway
- First half of 2029
- Ga expenses
- 7136000
- Rd expenses
- 20687000
- Cash position
- 452400000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.